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Abstract
Background: Although metformin, a first-line drug for treating diabetes, may play an important role in inhibition of
epithelial ovarian cancer cell growth and cancer stem cells (CSCs), metformin at low dose showed less effect on the
proliferation of ovarian cancer cells. In this study, we evaluated the effect of metformin at low dose on ovarian
CSCs in order to understand the molecular mechanisms underlying.
Methods: The inhibitory effects of metformin at los dose on proliferation and population of ovarian cancer cells
including SKOV3 and A2780 were assessed by cell proliferation assay and flow cytometry. Quantitative real-time
PCR assay on expression of Bcl-2, Survivin and Bax was performed to determine the effect of metformin at low
dose on epithelial-mesenchymal transition (EMT) of cancer cells and CSCs. Tumor sphere formation assay was also
performed to evaluate the effect of metformin on spheres forming ability of CSCs. The therapeutic efficacy and the
anti-CSC effects of metformin at low dose were investigated by using both SKOV3 cells and primary tumor
xenografts. In addition, the CSC frequency and EMT in tumor xenograft models were also assessed by flow
cytometry and quantitative real-time PCR.
Results: Metformin at low dose did not affect the proliferation of ovarian cancer cells. However, it inhibited
population of CD44+CD117+ selectively, neither CD133+ nor ALDH+ cells. It suppressed expression of snail2,
twist and vimentin significantly in cancer cells and CD44+CD117+ CSCs in vitro. Low dose of metformin reduced
survivin expression in CSCs. Low concentrations of metformin inhibited the secondary and the tertiary tumor
sphere formation, decreased SKOV3 and primary ovarian tumor xenograft growth, enhanced the anticancer effect
of cisplatin, and lowered the proportion of CD44+CD117+ CSCs in the xenograft tissue. Metformin was also
associated with a reduction of snail2, twist, and vimentin in CD44+CD117+ ovarian CSCs in vivo.
Conclusions: Our results implicate that metformin at low dose inhibits selectively CD44+CD117+ ovarian CSCs
through inhibition of EMT and potentiates the effect of cisplatin.
Keywords: Metformin, Epithelial–mesenchymal transition, Ovarian cancer stem cells
* Correspondence: liwentao98@126.com; sunstem1@163.com
†Equal contributors
3Department of Interventional Radiology, Cancer Hospital, Fudan University,
Shanghai 200032, China
5Sunstem Biotechnology Co., Ltd, Shanghai 200439, China
Full list of author information is available at the end of the article
© 2015 Zhang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. Stem Cell Research & Therapy  (2015) 6:262 
DOI 10.1186/s13287-015-0249-0
Background
Ovarian cancer is the fifth most common type of can-
cer in females and the leading cause of mortality for
gynecological malignancies. Epithelial ovarian cancer
(EOC) accounts for more than 90 % of all ovarian
neoplasms [1, 2].
To understand the exact biological features of ovarian
carcinoma, series of new studies are being focused on can-
cer stem cells (CSCs). Study of CSCs suggests that these
are a rare population of cancer cells with inherent che-
moresistance, capable of regeneration of the various cell
types within tumors, which then leads to relapse of therapy
[3, 4]. Drugs targeting CSCs may offer great promise for
the development of novel anticancer drugs. Highly diversi-
fied phenotypes in ovarian CSCs have been found.
Well-studied cell surface biomarkers including CD44/
CD117, CD133, and aldehyde dehydrogenase (ALDH)
are used extensively to identify ovarian CSCs [5–11].
Metformin, a traditional medication for type 2 dia-
betes, has been demonstrated to have antiproliferative
and proapoptotic effects on ovarian cancer [12], and has
been used to target CSCs in ovarian cancer [6]. Recent
studies indicated that metformin can inhibit the growth
and the proliferation of ovarian CSCs in vitro and in vivo.
These results provide a rationale for using metformin to
treat patients with ovarian cancer [6].
The epithelial–mesenchymal transition (EMT) is a
process by which an epithelial cancer cell loses its cell
polarity and cell–cell adhesion and acquires the capacity
to migrate and metastasize. Epithelial cancer cells through
EMTcan undergo a phenotypic switch, which allows these
polarized and immobile epithelial cells to become motile
mesenchymal cells [13–15]. EMT has been linked to the
ability for self-renewal and generation of multiple lineages
[14]. Although the latest studies showed that EMT
can initiate regeneration of CSCs from immortalized
human mammary epithelia [14, 16, 17], the molecular
mechanism underlying regeneration of CSCs through
EMT is unknown.
A series of studies has shown that metformin may re-
press the EMT transcriptionally and repress a cell pheno-
type associated with CSCs in breast cancer [18, 19]. It
also inhibited cellular transformation and killed breast
CSCs selectively in vitro and in vivo [19]. Snail1 and
snail2 are key transcriptional factors to regulate progres-
sion, functionality, and survival of metastatic ovarian
stem cancer cells. Activation of Snail1 and Snail2 re-
sults in regeneration of stem-like cells through EMT,
causing cellular resistance to the therapy and failure
of p53-mediated apoptosis, and leading to activation
of a self-renewal program [20].
Although the dose of metformin used in the clinic is
much lower than that used in most research, metformin
at a dose less than 1 mM shows less effect on
proliferation of ovarian cancer cells in vitro [6]. How-
ever, a recent study of pancreatic cancer showed that
metformin at low concentrations selectively inhibited
the proliferation and the invasive capacities of CD133+
cells in vitro, and of pancreatic cancer xenograft growth
in vivo [21]. Recently, data from a study suggested that
metformin at low dose might transform ovarian cancer
cells or CSCs into noncancerous cells by reprogramming
CSCs, leading to benefit in patients who had these can-
cers with minimal side effects [22].
In this study, we hypothesized that metformin at low
dose inhibits growth of ovarian cancer cells, and found
that metformin at low dose inhibited proliferation of
ovarian CSCs both in vitro and in vivo, suggesting a
novel mechanism underlying inhibitory effects of met-
formin on ovarian CSCs.
Methods
Cell culture
The human ovarian cancer cell lines SKOV3 and A2780
were obtained from the Cell Bank of the Shanghai Insti-
tute of Biochemistry & Cell Biology, Shanghai Institute
for Biological Sciences, Chinese Academy of Sciences,
Shanghai, China (http://www.cellbank.org.cn), and were
cultured in RPMI-1640 medium supplemented with 10 %
fetal bovine serum (Gibco, Grand Island, NY, USA). All
cell lines were maintained in a humidified atmosphere at
37 °C with 5 % CO2. For tumor spheres culture in vitro,
cells were plated in ultralow attachment six-well plates
(Corning Inc., Corning, NY, USA) at a density of 10,000
cells per well in serum-free endothelial basal medium-2
(Lonza, Basel, Switzerland) with 10 ng/ml leukemia in-
hibitory factor (Sigma. St. Louis, MO, USA), 20 ng/ml
human fibroblast growth factor-2 (Sigma. St. Louis,
MO, USA), or 20 ng/ml epidermal growth factor
(Gibco, Grand Island, NY, USA). Sphere cultures were
passaged every 7–10 days. To passage spheres, media were
removed and spheres were incubated at room temperature
for 5 minutes in 0.05 % trypsin (Gibco, Grand Island, NY,
USA). Spheres were observed under the microscope to
verify dissociation. Cells were then washed with Hanks’
buffered salt solution (HBSS; Gibco) and filtered
through a 40 nm strainer before replanting.
Cell proliferation assays
Cells were cultured at a density of 3 × 103 cells per well
in 96-well plates in RPMI-1640 media with 10 % fetal
bovine serum (FBS). After 24 hours, Cell Titer 96H Aque-
ous One Solution Reagent (Promega, Madison, WI, USA)
was added to each well according to the manufacturer’s
instructions. After culture for 2 hours, cell viability was
determined by measuring the absorbance at 490 nm using
a Bio-Rad plate-reader (Hercules, California, CA, USA).
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Quantitative real-time PCR
cDNA was first synthesized using equivalent amounts of
total RNA (0.5-1 μg) with random primers in a 20 μl
reverse-transcriptase reaction mixture (Promega). Real-
time quantitative RT-PCR (Taqman) primers for snail1,
snail2, twist, vimentin, E-cadherin, and β-actin were
designed and purchased from Applied Biosystems as
Assay-on-Demand™ Gene Expression Products. Real-
time RT-PCR was performed following the supplier’s
directions. The 20 μl PCR mixture contained 10 μl of
2× Taqman universal PCR master mixes, 1 μl of 20×
working stock of expression assay mix, and 50 ng RNA
converted DNA. Real-time PCR was performed in an ABI
PRISM 7900HT sequencing detection system (Applied
Biosystems, Foster City, CA, USA). The assay for each
sample was performed in triplicate. Fluorescence of the
PCR products was detected using same apparatus. The
number of cycles required for the amplification plot
to reach the threshold limit, the Ct value, was used
for quantification.
Western blotting assay
Immunoblot analysis was performed using antibodies
against snail1, snail2, twist, vimentin, E-cadherin, and
β-actin (Cell Signaling Technology, Beverly, MA, USA)
diluted according to the manufacturers’ instructions. After
analysis, the blots were stripped, washed, and reprobed
with β-actin antibody to serve as a loading control. Pro-
tein expression was quantified using a Kodak Gel Docu-
mentation System (model 1D 3.6; Kodak, Rochester, NY,
USA).
Preparation for single cell suspensions of tumor cells
Before digestion with collagenase, xenograft tumors were
cut up into small pieces with scissors, and then minced
completely using sterile scalpel blades. To obtain single
cell suspensions, the resultant minced tumor pieces were
mixed with ultra-pure collagenase IV (Worthington
Biochemical, Lakewood, NJ, USA) in medium 199 (200
units of collagenase per ml) and allowed to incubate at
37 °C for 2.5–3 hours for enzymatic dissociation. The
specimens were further mechanically dissociated every
15–20 minutes by pipetting with a 5 ml pipette. At the
end of the incubation, cells were filtered through a 40 μm
nylon mesh and washed with HBSS/20 % FBS, and then
washed twice with HBSS.
Flow cytometry
Dissociated cells were counted and transferred to a 5 ml
tube, washed twice, and resuspended in HBSS with 2 %
FBS at concentrations of 106 cells per 100–200 μl.
Sandoglobin solution (1 mg/ml) was then added to the
sample at a dilution of 1:20 and the sample was then
incubated on ice for 20 minutes. The sample was then
washed twice and resuspended with HBSS containing
2 % FBS. Antibodies were incubated for 20 minutes on
ice, and the sample was washed twice with HBSS contain-
ing 2 % FBS. When needed, a secondary antibody was
followed by a 20-minute incubation. After another wash-
ing, cells were resuspended in HBSS buffer containing
4′,6-diamidino-2-phenylindole (DAPI; 1 μg/ml). The
antibodies used were anti-CD44 allophycocyanin (APC),
anti-CD117 (PE), anti-CD133 (FITC), and anti-H2K
(PharMingen, Franklin Lakes, NJ, USA), each at a dilution
of 1:40. In all experiments using human xenograft tissue,
infiltrating mouse cells were eliminated by discarding
H2K (mouse histocompatibility class I) cells during flow
cytometry. Dead cells were eliminated using the viability
dye DAPI. ALDH enzymatic activity was assessed using
the ALDEFLUOR kit as per the manufacturer’s protocol
(Stem Cell Technologies, Vancouver, BC, Canada). Cells
treated with ALDH inhibitor diethylaminobenzaldehyde
(DEAB; 50 mM/l) were used as control. Flow cytometry
was performed on a FACS Aria machine (BD Immunocy-
tometry Systems, Franklin Lakes, NJ, USA). Side scatter
and forward scatter profiles were used to eliminate cell
doublets. Cells were routinely sorted twice, and the cells
were reanalyzed for purity, which typically was greater
than 97 %.
Analysis of cell cycle analysis
For cell cycle analysis by flow cytometry, cells were fixed
with 70 % ethanol overnight at 4 °C. Cell pellets were
then suspended in 300 μl phosphate-buffered saline (PBS)
containing 100 μg/ml RNase for 30 minutes at room
temperature, and then 10 μg/ml propidium iodide (Cal-
biochem, San Diego, CA, USA) were added. The distribu-
tion of cells in the different phases of the cell cycle was
analyzed from DNA histograms using BD Cell Quest soft-
ware (Becton Dickinson Biosciences, San Diego, CA, USA).
Subcutaneous implantation of cells in NOD-SCID mice
Single cell suspensions (5 × 105 cells) were made with
serum-free RPMI/Matrigel (BD Bioscience, San Jose,
CA) mixture (1:1 volume) and injected subcutaneously
into the right and left mid abdominal area of 8-week-old
male nude mice using a 27-gauge needle. Mice obtained
from Shanghai SLAC Lab. Animal Co., Ltd (Shanghai,
China) were monitored daily for tumor growth. The treat-
ments were started when the tumor size reached approxi-
mately 150 mm3, and then mice received no treatment,
metformin 20 mg/kg intraperitoneally (i.p.) daily, cisplatin
250 μg/kg i.p. for 3 days, or cisplatin 250 μg/kg i.p. plus
metformin 20 mg/kg i.p. daily. Tumor growth was
measured using calipers, and animals underwent autopsy
at 4 and 9 weeks after treatment and tumor growth was
assessed. All experiments in this study were approved by
the local institutional review board and ethics committee
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at the authors’ affiliated institutions and animal experi-
ments were carried out in accordance with the estab-
lished institutional guidelines for animal care and use
of Laboratory Animals of the Shanghai Jiao Tong Univer-
sity (Shanghai, China).
Statistical analysis
Data are expressed as the mean ± standard error. Sta-
tistically significant differences were determined by the
unpaired Student’s t test between two groups and one-
way analysis of variance followed by Dunnett’s test
between multiple comparisons. P <0.05 was considered
significant.
Results
Metformin at low dose decreased CD44+CD117+ CSCs
Metformin at a dose range of 0.03-0.3 mM showed no
significant inhibitory effect on two ovarian cancer cell
lines (Fig. 1). Flow cytometry assay was performed by
analysis of the percentage of ALDH+, CD133+, and
CD44+CD117+ cells in SKOV3 and A2780 cells treated
with metformin at a dose range of 0.03–0.3 mM for 72
hours. Metformin at low dose resulted in a 2.5-fold
decrease in the CD44+CD117+ CSC population at a
metformin dose of 0.1 mM and in a 2.8-fold decrease at a
dose of 0.3 mM in SKOV3 cells (Fig. 2a). Metformin
caused a 2.5-fold decrease in the CD44+CD117+ CSC
population at a dose of 0.1 mM and a threefold decrease
at 0.3 mM in A2780 cells (Fig. 2d). However, metformin
showed no inhibitory effect on both CD133+ and ALDH+
subpopulations in the dose range of 0.03–0.3 mM
(Fig. 2b, c, e, f ).
Metformin inhibited both EMT of SKOV3 cells and EMT of
CD44+CD117+ CSCs
To investigate the effect of metformin at low dose (0.1
mM) on the EMT of SKOV3 cells, SKOV3 cells were
treated with metformin at 0.1 mM for 72 hours and ex-
pression of EMT components, including snail1, snail2,
twist, vimentin, and E-cadherin, was then analyzed by
quantitative real-time PCR. We observed that metformin
at 0.1 mM showed no effect on snail1 expression, a 2.3-
fold decrease on snail2, a 2.4-fold decrease on twist, a
3.4-fold decrease on vimentin, and a 1.9-fold increase on
E-cadherin (Fig. 3a). Western blotting assay showed
that metformin increased significantly the expression
of E-cadherin and decreased snail2, twist, and vimen-
tin, which were consistent with the quantitative RT-
PCR results (Fig. 3b). To determine expression of the
EMT biomarkers, flow cytometry was used to isolate
CD44+CD117+ cells. Data from quantitative real-time
PCR showed that metformin at 0.1 mM caused no change
in snail1 expression, but a 5.9-fold decrease for snail2, a
5.6-fold decrease for twist, a 7.7-fold decrease for vimen-
tin, and a 2.32-fold increase for E-cadherin (Fig. 3c).
Metformin reduced the CD44+CD117+ subpopulation of
ovarian CSCs by inhibition of its self-renewal
To study whether metformin inhibits subpopulation of
ovarian cancer cells, CD44+CD117+ SKOV3 cells were
sorted and grown in the presence or absence of metfor-
min. The results showed that metformin at 0.1 mM
decreased the CD44+CD117+ cell population inside
tumorspheres significantly, as shown in Fig. 4c. To deter-
mine the inhibitory effects of metformin on self-renewal
of CSCs, sorted CSCs were treated with metformin at 0.1
mM. The results showed that first-passage sphere forma-
tion was not significantly different regardless of metformin
at 0.1 mM. However, the significant inhibitory effects of
metformin at 0.1 mM on formation of new tumorspheres
was observed as passaging went on. Cells at passage 3
treated with metformin at 0.1 mM showed an approxi-
mately fourfold decrease in their ability to form new
tumor spheres as compared with controls (Fig. 4a, b).
Fig. 1 Low concentrations of metformin did not inhibit the proliferation of pancreatic cancer cells. SKOV3 (a) and A2780 (b) cells were incubated
with different concentrations of metformin for 72 hours and numbers of viable cells were determined by cell proliferation assay
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Fig. 2 (See legend on next page.)
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Metformin at low dose inhibited proliferation of
CD44+CD117+ cells by significantly reducing Survivin
expression
To study whether metformin affects proliferation of
the subpopulation of CD44+CD117+ cells, the sorted
CD44+CD117+ cells were treated with metformin at
0.1 mM. The results showed that metformin treatment
caused a 6.7-fold decrease in Survivin expression, and a
1.7-fold increase in Bax expression, without change in the
Bcl-2 level (Fig. 4d). However, metformin did not affect
the cell cycle activity of CD44+CD117+ cells (Fig. 4e).
Metformin at low dose decreased CSCs and reduced EMT
in SKOV3 xenograft mice
To further evaluate the therapeutic efficacy of metfor-
min, human ovarian cisplatin-resistant SKOV3 tumor
xenografts were used. Both metformin and cisplatin alone
slightly inhibited tumor growth during 4 weeks of treat-
ment (Fig. 5a, b). Following cessation of treatment, tumors
in the metformin and cisplatin treatment groups grew less
than the untreated tumors, demonstrating that treat-
ment with metformin and cisplatin resulted in a delay
of tumor growth. However, tumors grew much slower
Fig. 3 Low concentrations of metformin reduced EMT of ovarian cancer cells and the CD44+CD117+ CSC population. SKOV3 cells were incubated
with 0.1 mM metformin for 72 hours. The CD44+CD117+ cells were isolated by flow cytometry. Total RNA was isolated and mRNA was quantitated by
real-time RT-PCR. mRNA expression of snail1, snail2, twist, vimentin, and E-cadherin was analyzed. Data show that treatment with 0.1 mM metformin
reduced snail2, twist, and vimentin, but not snail1expression level, and upregulated the E-cadherin expression level (a). Bands detected with antibodies
indicate the immune reactivity for snail1, snail2, twist, vimentin, E-cadherin, and β-actin: 72 hours of treatment with 0.1 nM metformin significantly
downregulated snail2, twist, and vimentin, but not snail1, and upregulated E-cadherin as shown by western blotting (b). Total RNA was isolated from
CD44+CD117+ cells and the mRNA was quantitated by real-time RT-PCR. Metformin at 0.1 mM significantly reduced snail2, twist, and vimentin, but not
snail1 expression level, and upregulated the E-cadherin expression level (c). * Significant difference compared with control (P < 0.05)
(See figure on previous page.)
Fig. 2 Low concentrations of metformin selectively decreased the CD44+CD117+ ovarian cancer cell population. SKOV3 (a, b, c) and A2780 (d, e, f)
cells were incubated with different concentrations of metformin for 72 hours, and the proportions of cells expressing different CSC surface markers
were determined by flow cytometry. For both cell lines, the proportions of CD133+ and ALDH+ were not altered by treatment with low
concentrations of metformin (0.03–0.3 mM) (b, c, e, f), but the proportion of CD44+CD117+cells was reduced in a dose-dependent manner (a, d).
ALDH aldehyde dehydrogenase. * Significant difference compared with control (P < 0.05)
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in mice treated with both metformin and cisplatin
than after cessation of both treatments (Fig. 5b).
FACS plots of sorted cells harvested from tumors in
the different treatment groups demonstrate the effects
on the CD44+CD117+ population (Fig. 5c). Cisplatin
treatment resulted in an average increase of 77 % in
the CD44+CD117+ population, likely because these cells
are resistant to cell death from chemotherapy, similar to
the enrichment observed in pancreatic cancer ALDH+-ex-
pressing cells following cisplatin treatment [6]. Treatment
with metformin resulted in a 2.2-fold decrease in the
CD44+CD117+ population, suggesting that metformin
targeted the CSC population within the tumor. Combined
treatment with metformin and cisplatin prevented the
Fig. 4 Metformin inhibits CSCs in tumor spheres and regulates their self-renewal. Isolated CD44+CD117+ cancer cells were cultured in sphere
medium for 24 hours and then incubated with or without 0.1 mM metformin. Seven days of treatment with 0.1 mM metformin failed to inhibit
tumor sphere formation. Tumor spheres were then dissociated with 0.05 % trypsin and cultured in ultralow plates with 0.1 mM metformin. Metfor-
min at 0.1 mM inhibits CD44+CD117+ cells forming spheres with serial passaging (a, b). Metformin at 0.1 mM also reduced the CD44+CD117+ cell
population with serial passaging (n = 3) (c). Metformin at 0.1 mM significantly reduced Survivin but not Bcl-2 expression level, and upregulated Bax
expression level in CD44+CD117+ cells (d). Representative cell cycle histograms following flow cytometric analysis of propidium iodide (PI)-
stained CD44+CD117+ cells show no change in the percentage of cells entering the S phase upon 0.1 nM metformin treatment (e). * Sig-
nificant difference compared with control (P < 0.05)




Fig. 5 Metformin and cisplatin inhibit subcutaneous tumor growth in xenograft mice. Two to 4 weeks after subcutaneous injection of ovarian
SKOV3 cancer cells, the treatments were started when the tumor size reached approximately 150 mm3. Four groups of mice (n = 6) were treated
with saline, metformin, cisplatin, or the combination of metformin and cisplatin for 4 weeks. Tumor size and body weight were measured weekly
throughout the experiment period. Three mice of each group were sacrificed after 4 weeks of treatment for analysis and the other three mice
were kept to observe for an additional 5 weeks. Representative experiment showing the actual resected tumor of each treatment group (a).
Summary results from three separate experiments are presented (b). After 4 weeks of treatment, tumor tissues from each group were digested
with ultrapure collagenase IV to obtain single cell suspensions. Flow cytometry was performed to isolate CD44+CD117+ CSCs of each treatment
group. Metformin treatment significantly reduced the CD44+CD117+ CSC population (c). Total RNA was isolated from CD44+CD117+cells and
mRNA was quantitated by real-time RT-PCR. Metformin significantly reduced snail 2, twist, and vimentin, but not the snail1 expression level, and
upregulated E-cadherin expression (d). * Significant difference compared with control (P < 0.05)
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increase in the CSC population observed with cisplatin
treatment alone, resulting in a 2.6-fold decrease in the
CD44+CD117+ population compared with cisplatin treat-
ment alone, which increased in the CSC population, fur-
ther demonstrating that metformin is capable of targeting
the CSC population (Fig. 5c). The effect of metformin on
EMT markers’ expression of CD44+CD117+ cells was
analyzed by real-time RT-PCR. Data demonstrated that
0.1 mM metformin had no effect on snail1 expression, but
led to a 7.7-fold decrease for snail2, an 8.3-fold decrease
for twist, a 10-fold decrease for vimentin, and a 1.9-fold




Fig. 6 Metformin and cisplatin inhibit tumor growth in patient-derived xenograft mice. Six to 8 weeks after subcutaneous injection of ovarian pa-
tient ovarian cancer cells, the treatments were started when the tumor size reached approximately 150 mm3. Four groups of mice (n = 6)
were treated with saline, metformin, cisplatin, and the combination of metformin and cisplatin for 4 weeks. Tumor size and body weight were
measured weekly throughout the experiment period. Three mice from each group were sacrificed after 4 weeks of treatment for analysis and
the other three mice were kept to observe for an additional 5 weeks. Summary results from three separate experiments are presented (a). Flow
cytometry was performed to isolate CD44+CD117+ CSCs of each treatment group. Metformin treatment significantly reduced the CD44+CD117+
CSC population (b). Metformin significantly reduced snail2, twist, and vimentin, but not Snail1expression, and upregulated E-cadherin expression
(c). * Significant difference compared with control (P < 0.05)
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Metformin at low dose decreased CSCs and reduced EMT
in primary ovarian cancer xenograft mice
Data indicated that treatment with metformin or cisplatin
alone resulted in a delay of tumor growth. However, in the
group treated with metformin and cisplatin, tumor growth
was extremely slow, even near the cessation of treatment,
showing a significant enhanced anti-tumor effect (Fig. 6a).
The effect of metformin on expression of EMT marker
CD44+CD117+ was analyzed by real-time RT-PCR. We
obtained similar results when measuring the effect of
metformin, used alone or in combination with cisplatin,
on the CD44+CD117+ CSC population (Fig. 6b). Treat-
ment with metformin resulted in a 2.8-fold decrease in
the CD44+CD117+ population, and an increase of 2.2-
fold for cisplatin, and combined treatment with met-
formin and cisplatin resulted in a 4.6-fold decrease in
the CD44+CD117+ population compared with cisplatin
alone, and even a 2.1-fold decrease in the CD44+CD117+
population compared with control, further demonstrating
that metformin is capable of targeting the CSC population
(Fig. 6b). Real-time RT-PCR experiment demonstrated
that metformin had no effect on Snail 1 expression, but
led to a 11.1-fold decrease in Snail 2, a 10-fold decrease in
Twist, a 11.1-fold decrease in Vimentin expression, and a
2.9-fold increase in E-cadherin expression (Fig. 6c).
Discussion
In this study, we demonstrated that low concentrations
of metformin selectively inhibited CD44+CD117+ ovar-
ian CSCs through downregulation of EMT. Moreover,
we showed that low concentrations of metformin down-
regulated snail2, twist, and vimentin, leading to inhib-
ition of EMT, and downregulated Survivin expression to
increase apoptosis in the CD44+CD117+ cell population.
The efficacy study indicated that metformin also po-
tentiated the effect of cisplatin. Therefore, low concen-
trations of metformin may be used as a therapeutic
agent for killing ovarian CSCs.
Of clinical importance, CSCs have been hypothesized
to be resistant to conventional chemotherapy and radi-
ation therapy and to be responsible for cancer metastasis
and recurrence after clinical remission. For ovarian can-
cer, CSCs are also believed to be resistant to chemother-
apy and radiation therapy [23–25]. Metformin was active
against ovarian cancer cells in vitro and in vivo. Also,
metformin inhibited the growth of metastatic nodules in
the lung and significantly potentiated cisplatin-induced
cytotoxicity, resulting in approximately 90 % reduction
in tumor growth in ovarian cancers [26]. Shank et al. [6]
showed that metformin acted on ovarian CSCs, reducing
the percentage of ALDH+ CSCs in vitro and in vivo,
and inhibiting the growth of ovarian tumor spheres. In
addition, metformin therapy alone slowed the growth
of ovarian CSCs in vivo. Targeting Notch pathway of
ovarian CSCs sensitized tumors to cisplatin therapy
[27]. Low-dose metformin may reprogram ovarian can-
cer cells or CSCs into noncancerous cells [22]. These
studies indicate that cisplatin treatment enriches the
ovarian CSC population and that current treatments
for ovarian cancer do not address the unique survival
mechanisms of ovarian CSCs. It is therefore essential
to better understand CSC so that specific therapies
can be devised to target this population of cancer
cells. Our in vivo data are consistent with these early
findings, highlighting the significance of low-dose met-
formin in targeting CSCs.
Ovarian CSCs possess mesenchymal characteristics
and EMT ability [28]. Ovarian CSCs could be a source
of ovarian cancer metastasis through EMT and regula-
tion of TWIST-1 expression, and function is a critical
step in this process [29]. Ovarian CSCs that undergo the
EMT have demonstrated that the tumor cells are in
general less differentiable, more invasive, more chemore-
sistant, and result in poor clinical outcomes [29–31].
Chen et al. [9] demonstrated that the overexpression of
miR-200c significantly reduced the CD117+CD44+ CSC
xenograft growth and lung metastasis in vivo, partially
through the reversal of the EMT phenotype. Snail1 and
snail2 have also been associated with chemoresistance
and activation of stemness-associated pathways [32, 33].
Craveiro et al. [34] showed that snail2 is one of the more
significantly upregulated genes in paclitaxel-surviving
CSCs and snail2 overexpression was sufficient to yield
more aggressive and more chemoresistant tumors. In-
hibition of the EMT process by snail1 silencing reduced
the side population cell frequency, and affected their in-
vasive capacity and engraftment [35]. We therefore in-
vestigated the effect of metformin on EMT in CSCs,
focusing on snail1, snail2, and twist, and established the
connection between metformin and EMT of ovarian
CSCs.
We firstly studied the effect of metformin at low
concentration on the CSC population and found that
low concentrations of metformin selectively inhibited
CD44+CD117+ cells, but not CD133+ or ALDH+ cells,
likely through downregulated EMT. We found that
cisplatin could only kill the rapidly increased ovarian
tumor cells, while it could not inhibit the population
of CSCs. This is one of the reasons why many tumors
are recurring and resistant to chemotherapy drugs,
such as cisplatin. To study the effect of low concen-
trations of metformin on the function of CSCs, we
utilized an in vitro sphere-forming assay. We found that
using low concentrations of metformin decreased the CSC
population and EMT. Our results are consistent with pre-
vious work indicating that low-dose metformin inhibits
CSCs in other cancer types, such as pancreatic cancer and
breast cancer [18, 21].
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The underlying molecular mechanisms of metformin
inhibiting EMT in CSCs are not well understood. Lee et
al. [36] reported that induction of EMT in human retinal
pigment epithelial cells upregulates Survivin, leading to
Survivin-dependent inhibition of cell cycle arrest and
apoptosis. It has been reported that drug resistance of
ovarian CSCs were linked with Survivin [37]. Another
study indicated that metformin induced apoptosis in
ovarian cancer cells without significant cytotoxicity [38].
We found that metformin treatment resulted in apop-
tosis of ovarian CSCs by downregulating Survivin and
upregulating Bax. These results suggest that low concen-
trations of metformin reduce survival of ovarian CSCs.
We analyzed the efficacy of targeting ovarian CSCs in
xenografts of established ovarian cancers in nude mice
and found that treatment with low-dose metformin in
both SKOV3 and primary xenograft models resulted
in a marked decrease in the ovarian CSC population.
Both treatments with low-dose metformin alone or
cisplatin alone did not considerably inhibit tumor
growth, while treatment with both agents significantly
blocked tumor growth, even up to 5 weeks after ces-
sation of treatment. Low-dose metformin significantly
inhibited CD44+CD177+ CSCs and EMT in vivo, which is
consistent with our in vitro data. These data suggest that
using a combined therapy that targets both the ovarian
CSC population and the nontumorigenic bulk population
of ovarian cancer cells may be most efficacious in treating
patient symptoms associated with tumor mass and result
in eradication of the CSC population.
As evidence mounts to support the paradigm that a
small subset of cancer cells dictate the biologic behavior
of malignant disease, approaches in designing more effect-
ive therapeutic strategies must consider a new target—the
CSCs. Data have shown that ovarian cancers contain a
small population of CSCs responsible for tumor initiation
and propagation and resistance to conventional chemo-
therapy and radiation. Here we found that targeting low
concentrations of metformin may be useful in eradicating
CSCs and potentiate conventional chemotherapy. This
study provides data to support further exploration of low
concentrations of metformin, as a therapeutic target to
eradicate CSCs from human ovarian tumors, which may
prevent ovarian cancer recurrence and improve long-term
survival.
Conclusions
This research indicates that low concentrations of met-
formin selectively inhibit CD44+CD117+ ovarian CSCs
through inhibitions of EMT and potentiate the effect of
cisplatin. The present study may support the new clinical
applications of metformin, which will prevent ovarian
cancer recurrence and will improve long-term survival.
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